Can a common seed oil boost stomach infection treatment?
NCT ID NCT05957432
First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time
Summary
Researchers test whether adding black seed oil to a vonoprazan-based triple therapy clears Helicobacter pylori infection better than the standard triple therapy alone. The trial enrolls 90 adults with confirmed H. pylori who have not been treated before. Participants receive either the combination or the standard therapy, and researchers measure infection clearance, markers of inflammation and oxidative stress, stomach symptoms, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- black seed oil added to vonoprazan-based triple therapy
- What this could lead to
- If it works, adding black seed oil could offer a way to improve H. pylori clearance and reduce stomach symptoms with fewer side effects.
- What could go wrong
- This is a small Phase 2 trial, so results may not hold in larger groups. Black seed oil can cause stomach upset, and the triple therapy carries risks of nausea, diarrhea, and allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 90 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2023
- Expected to finish
-
Nov 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female patients * Age 18 to 75 years old * Patients with confirmed H. pylori infection by stool Ag test who had not received prior eradication therapy Exclusion Criteria: * History of hypersensitivity / allergy to any of the study drugs i.e., Esomeprazole, vonoprazan, penicillin, or clarithromycin * History of previous H. pylori eradication therapy * History of using PPIs, antibiotics that affect H. pylori within 4 weeks * History of gastric malignancy or surgery * Serious cardiovascular, pulmonary, renal, hepatic disorders or active malignancy * Pregnancy or breast feeding * History of drug abuse or active alcohol abuse
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Helicobacter pylori infection are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GIT department zagazig university hospital
Zagazig, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heartburn drug under the microscope: registry tracks thousands of pregnancies
- Can probiotics make h. pylori antibiotics easier on the gut?
- Two antibiotic cocktails face off to wipe out stomach bacteria
- Could a routine blood count reveal hidden stomach infection?
- A simple breath test after a heart attack could prevent dangerous bleeding
- Can a Two-Step antibiotic plan beat stomach bacteria?